New drug combo may reduce side effects in kidney transplant recipients
NCT ID NCT06034925
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two different medicines to prevent CMV infection in 70 kidney transplant patients at high risk. One group received the standard drug valganciclovir, while the other received maribavir plus acyclovir. The goal was to see which approach caused fewer side effects like low white blood cell counts, while still preventing CMV infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CMV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test could tailor CMV prevention after stem cell transplants
- Massive UK study tracks cancer after organ transplants
- New drug may offer safer CMV prevention for kidney transplant patients
- New hope for lung transplant patients: drug may block dangerous virus
- New blood test may help protect kids from post-transplant infection
- Hidden virus in Kids' guts: new study sheds light on CMV and IBD